Association of plasma lactate level with 28-day mortality in non-elderly and elderly sepsis patients: A retrospective cohort study based on the MIMIC- database

Yihua Dong  
Wenzhou Medical University First Affiliated Hospital

Xiaoyang Miao  
Wenzhou Medical University First Affiliated Hospital

Yufeng Hu  
Wenzhou Medical University First Affiliated Hospital

Yueyue Huang  
Wenzhou Medical University First Affiliated Hospital

Jie Chen  
Wenzhou Medical University First Affiliated Hospital

Yingru Lu  
Wenzhou Medical University First Affiliated Hospital

Jingye Pan (everydayisbetter@126.com)  
Wenzhou Medical University First Affiliated Hospital  
https://orcid.org/0000-0002-2367-1275

Research article

Keywords: sepsis, lactate, mortality, MIMIC database

DOI: https://doi.org/10.21203/rs.2.11631/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Purpose:** The objective of this study is to assess the clinical usefulness of lactate as a predictor of 28-day mortality and the relationship between lactate and 28-day mortality in non-elderly (<65 years) and elderly (≥65 years) sepsis patients who were admitted to an intensive care unit (ICU).

**Methods:** This retrospective study used the Medical Information Mart for Intensive Care (MIMIC-II), a publicly available database of ICUs. Prognosis was evaluated using receiver operating characteristic (ROC) analysis. Univariate and multivariable binary logistic regression models were used to identify the association lactate with 28-day mortality. We converted continuous variable lactate into a categorical variable based on tri-segment quantile to explore segmentation effects.

**Results:** The average age of 2848 patients was 68.01 years old, and about 55.40% of them were male. The overall 28-day mortality was 30.41%, and the rate in elderly patients was 65.82%. Among non-survivors, the lactate level was significantly greater for the non-elderly than the elderly. Lactate level was positively associated with risk of 28-day mortality of the non-elderly sepsis patients (p for trend < 0.001), but there was no significant association between lactate level and 28-day mortality in the elderly group (p for trend = 0.830). The association between lactate and 28-day mortality for sepsis patients without liver cirrhosis was stronger than for sepsis patients with liver cirrhosis (OR 1.28 vs. OR 1.10, P =0.027).

**Conclusion:** Increased lactate level is associated with higher 28-day mortality in the non-elderly sepsis patients, but there is no significant association between the lactate level and 28-day mortality in the elderly group.

Background

The plasma lactate level is an important biomarker that reflects the oxygen metabolism of tissues. The root cause of septic shock is tissue hypoxia, and this leads to an increased level of glucose, anaerobic glycolysis, and lactate production [1]. Persistent hyperlactatemia, which suggests that tissue hypoxia has not been corrected, is associated with adverse outcome. Plasma lactate has been suggested as a biomarker for diagnosis and prognostic evaluation of sepsis [2]. An elevated level of plasma lactate during sepsis is associated with more severe disease and poor prognosis [3]. Previous studies revealed a relationship between lactate and mortality of patients with sepsis [4,5] and indicated that patients who presented with lactate>4mmol/L are significantly associated with in-hospital mortality[4]. However, they only focus on the overall population and did not specifically address the relationship between different lactate level and mortality in different age groups. Therefore, this study aims to investigate whether lactate is independently associated with 28-day mortality and the relationship between lactate and 28-day mortality in non-elderly (<65 years) and elderly (≥65 years) sepsis patients who were admitted to ICU.

Methods

**Data source**
The rapid development of medical information resources has made a large number of electronic health records available [6]. Analysis of these records has been a focus of significant research in medical research and related fields [7]. The Medical Information Mart for Intensive Care (MIMIC-III), which we used for the present study, is a publicly available database developed by the Laboratory of Computational Physiology at the Massachusetts Institute of Technology. This database integrates comprehensive clinical data from ICU patients who received care at the Beth Israel Medical Center from 2001 to 2012. It has de-identified data on demography, vital signs, laboratory tests, medical records, imaging reports, drug use, and other clinically significant information [8]. Researchers and institutions around the world have published numerous studies based on analysis of the MIMIC database [9-13].

**Study population**

The MIMIC-III database was used to identify all adults diagnosed with sepsis, severe sepsis, or septic shock with a first ICU admission. All included patients were at least 18 years-old and were hospitalized for at least 24 h. Patients whose initial lactate and chart events were not recorded were excluded.

The gold standard used for diagnosis of sepsis was the 2001 consensus definition [14], which defines sepsis as infections consisting of 2 or more systemic inflammatory response syndrome (SIRS) criteria (temperature above 38°C or below 36°C, heart rate greater than 90/min, respiratory rate greater than 20/min or PaCO2 below 32 mmHg, and white blood cell count greater than 12,000 or less than 4000 cells/mL or more than 10% band forms) [14].

**Study design**

Independent variables (including demographic characteristics, major complications, major infection sites, laboratory data, vital signs, mortality prediction scores, and 28-day prognosis) were extracted from MIMIC-III via PostgreSQL, a structured query language with Navicat Premium 12. Baseline features of the patients were recorded within 24h upon first admission to ICU. Lactate level was categorized as low, intermediate, or high. The primary outcome was 28-day mortality.

**Methods of analysis**

Continuous variables are expressed as medians and inter-quartile range, and the Mann-Whitney U test was used for comparisons. Categorical variables are expressed as numbers and percentages, and were compared using the chi-square test or Fisher exact test. Prognosis was evaluated using receiver operating characteristic (ROC) analysis, and the ability of lactate to predict 28-day mortality was assessed by calculating the area under the ROC (AUROC). Youden's index was used to assess the performance of the diagnostic test, and the maximum point of Youden's index was used as the cut-off point (sensitivity + specificity –1).

Univariate and multivariate binary logistic regression were used to identify the association between lactate and 28-day mortality of sepsis patients. The Hosmer-Lemeshow test was used to evaluate the suitability of the model. The results were shown as ORs (95% CIs). To investigate the possibility of linearity, we converted continuous variable lactate into a categorical variable based on tri-segment quantile and calculated P values.
Data were analyzed with the use of Empower (R) (www.empowerstats.com; X&Y solutions inc.) and the statistical packages R (The R Foundation; http://www.r-project.org; version 3.4.3). For all analyses, a P value below 0.05 was considered significant.

Results

Baseline characteristics

There were 46,476 patients who were first admitted to the ICU, and 3512 had diagnoses of sepsis (ICD 995.91), severe sepsis (ICD 995.92), or septic shock (ICD 785.52; Figure 1). After exclusion of 5 patients who were younger than 18 years-old, 309 patients who were discharged from the ICU within 24 h, 4 patients who did not have chart event data, and 346 patients whose initial lactate levels were not measured, there were 2848 patients. Among these 2848 patients, 1249 were younger than 65 years and 1599 were 65 years or older.

The average age of 2848 patients was 68.01 years old, and about 55.40% of them were male. The overall 28-day mortality rate was 30.4%, and the rate in elderly patients was 65.82%. Most patients in the non-elderly and elderly groups were male. The non-elderly patients stayed in ICU for more days, but the 28-day mortality was significantly greater in the elderly group. The baseline clinical and demographic characteristics of the survivors were compared to the non-survivors in each age group (Table 1). Analysis indicated the mortality rate increased with age within each age group, and that time in the ICU had a negative association with survivorship only in the elderly group. The non-survivors had a higher score of SAPSII, SOFA, LODS, OASIS, and lactate (p<0.001 for all). Analysis of major complications indicated the incidence of liver cirrhosis, chronic renal insufﬁciency and malignancy were signiﬁcantly greater among non-survivors in each age group. Further analysis (Table 2) showed that the lactate was similar for elderly and non-elderly survivors (2.20 vs. 2.10 mmol/L, P = 0.062), but was greater in non-elderly non-survivors than elderly non-survivors (3.20 vs. 2.40 mmol/L, P< 0.001).

Predictive values of lactate and some severity scoring systems for 28-day mortality

Table 3 lists the predictive values of lactate and some severity scoring systems in the two age groups for 28-day mortality. Their ROC curves are shown in Fig.2 and Fig.3. The predictive value of lactate for 28-day mortality was 0.661 for the non-elderly group, and 0.553 for the elderly group. The predictive performance of QSOFA and SIRS for 28-day mortality increased after lactate was added, but there was no significant difference in the AUROC values of SAPSII/ SOFA and LODS before and after lactate addition in the two age groups.

Association of lactate with 28-day mortality for each age group

In our study, there were 296 dead patients in the non-elderly group and 570 dead patients in the elderly group. We developed different models to examine the independent predicting value of lactate for 28-day mortality and used multivariate analysis to determine the impact of lactate on mortality in each group. The adjusted ORs (95%CIs) for lactate were 1.16 (1.09-1.23) and 1.03 (0.98-1.08) for 28-day mortality in the non-elderly and elderly group, respectively.
To test the nonlinear trend between lactate and 28-day mortality in septic patients of each age group, we converted the continuous variable of lactate into a categorical variable according to tri-segment quantile in the models and divided lactate into three levels. Lactate levels in the non-elderly group were probably consistent with those in the elderly group. We initially used univariate logistic regression analysis to identify variables related to 28-day mortality. The subsequent multivariate logistic regression analysis, in which patients with low level of lactate were used as the reference group, indicated increased lactate level was associated with 28-day mortality. A significant trend in higher mortality was observed in patients with elevated lactate level compared to patients with less level of lactate in the non-elderly group (p < 0.05 for all). Lactate level was positively associated with risk of death at 28 days in the non-elderly group (p for trend < 0.001), but there was no such correlation in the elderly group (p for trend = 0.830).

**Subgroup Analyses**

A stratified analysis was conducted by baseline characteristics. In the subgroup analyses, we used sex, ethnicity, first care unit, severity scoring systems, comorbidities and major source of infection as the stratified variables to examined the associations between lactate and 28-day mortality (Table 5). There was no significant difference in relationship between lactate and risk of 28-day mortality in the elderly group in the subgroup analyses. We observed significant changes in SAPSII, SOFA, liver cirrhosis and intra-peritoneal infection (p < 0.05 for all) (Fig.4). It was worth mentioning that we found significant inverse association of liver cirrhosis with 28-day mortality among the non-elderly sepsis patients. The lactate of the non-elderly patients without liver cirrhosis had a higher risk of 28-day mortality (OR 1.28, p < 0.0001). The association between lactate and 28-day mortality for sepsis patients without liver cirrhosis was stronger than for sepsis patients with liver cirrhosis in non-elderly group (OR 1.28 vs. OR 1.10, P=0.027 for the interaction lactate* liver cirrhosis for 28-day mortality).

**Discussion**

In this study, we retrospectively analyzed the clinical characteristics, 28-day mortality rate, and the relationship of plasma lactate level with the prognosis of sepsis patients in different age groups in the MIMIC-III database. Our results suggested that higher lactate level was associated with higher 28-day mortality in the non-elderly sepsis patients, but there was no significant association in the elderly group.

The clinical mortality rate of sepsis is now higher than that of myocardial infarction and, except for heart disease, sepsis is the main cause of death in the ICU [15]. The ultimate cause of death from sepsis is organ dysfunction caused by the patient’s reaction to the infection [16]. Because of their reduced immune responses and resistance, sepsis more common among the elderly. The prevalence and mortality of severe sepsis have increased significantly over time [17].

Most of these patients were from an emergency department, so those with high lactate levels were treated soon after admission. This may have contributed to the lower overall lactate levels in our study than in a previous study [18].

As a product of hypoxia and hypoperfusion, plasma lactate can be used to guide the judgment of fluid resuscitation and curative effect in patients with sepsis, and it is also an effective predictor of sepsis mortality.
Lactate is a well-known predictor of infection and trauma in patients and has been recognized as a biomarker for risk-stratification, especially in sepsis patients. Mikkelsen ME et al. [3] proposed initial serum lactate was associated with mortality independent of clinically apparent organ dysfunction and shock in patients admitted to the ED with severe sepsis. A previous study [20] reported that elevated lactate level was associated with poor prognosis for ICU patients after ruptured abdominal aortic aneurysm repair.

The elderly patients are more likely than the nonelderly to develop sepsis due to Gram-negative bacteria, especially among patients with pneumonia and fungal infections. Respiratory tract infections are also more common causes of sepsis in elderly patients [21]. Relative to the non-elderly, we found that elderly sepsis patients had a higher 28-day mortality rate and that sepsis was more likely to be caused by a respiratory tract infection, in agreement with previous studies [18, 22]. In contrast, we found that sepsis in non-elderly patients was more likely to be caused by skin and soft tissue infections.

The major indicators of poor prognosis in elderly sepsis patients are shock, elevated plasma lactate, and organ failure (especially of the respiratory system or heart) [23]. In addition, previous research indicated that advanced age is an independent risk factor for severe sepsis and death from sepsis [24]. Our multivariate adjusted logistic regression analysis showed that lactate level was an independent risk factor for 28-day mortality for non-elderly sepsis patients, but this relationship was not significant for the elderly. This might be a result of blunted inflammatory responses in the elderly.

We were surprised to find that the association between lactate and 28-day mortality for sepsis patients without liver cirrhosis was stronger than in sepsis with liver cirrhosis in non-elderly group. Some patients have high plasma lactate levels due to liver dysfunction leading to lactate removal dysfunction, but patients with normal or moderate lactate levels may have a higher risk of death[25], the interpretation of serum lactate levels is often complex. Therefore, a randomized controlled trial is necessary to examine whether liver insufficiency affects the relationship between lactate and the risk of death.

There are some limitations in this study. First, the patient information we used for analysis was only from the MIMIC-III database. The results may have bias, but the advantage of population size in our study may reduce the bias. Second, we could not analyze data from patients excluded due to missing lactate values. Although this is one of our potential limitations, we think that the characteristic of study with a relatively large number of patients may reduce the drawback. In addition, we compared the 28-day mortality in patients with lactate and without lactate values. There was no significant difference between the two groups (p=0.281). Finally, further forward-looking, large sample validation and risk grading studies are necessary to conduct to find more simple and effective prediction methods and achieve targeted interventions to reduce the incidence of death.

Conclusions

A significant trend in higher mortality was observed in patients with elevated lactate levels compared to patients with less level of lactate in the non-elderly group. Lactate level was positively associated with risk of 28-day mortality of the non-elderly sepsis patients, but there was no significant association between lactate level and 28-day mortality in the elderly group.
Abbreviations

ICU: Intensive Care Unit; MIMIC-III: the Medical Information Mart for Intensive Care III; ROC: receiver operating characteristic; AUROC: the area under the receiver operating characteristic curve; OR: odd ratio; SpO2, peripheral capillary oxygen saturation; MICU, medical intensive care unit; CCU, coronary care unit; TSICU, trauma surgical intensive care unit; CSRU, cardiac surgery recovery unit; SICU, surgical intensive care unit; SAPSII, simplified acute physiology score II; SOFA, sequential organ failure assessment; LODS: logistic organ dysfunction system; OASIS: oxford acute severity of illness score; QSOFA: quick sepsis related organ failure assessment; SIRS: systemic inflammatory response syndrome.

Declarations

Acknowledgments

The authors would like to thank MIMIC program for access to the database.

Funding

No funding was obtained for this study.

Availability of data and materials

The datasets analyzed during the current study are available in https://github.com/MIT-LCP/mimic-code/tree/master/concepts.

Authors’ contributions

YHD designed the methods and experiments, and contributed to the writing of manuscript. XYM and YFH cleaned the data. YYH, JC and YRL provided guidance and reviewed the manuscript critically. JYP supervised the study and revised the paper. All authors read and approved the final manuscript.

Ethics declarations

Ethics approval and consent to participate

Ethical consent was not required in this study, since the MIMIC data were analyzed namelessly.

Consent for publication
The manuscript does not include individual person's data.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(Suppl 9):3685-92.

2. John L Moran, John Santamaria. Reconsidering lactate as a sepsis risk biomarker. PLoS One, 2017, 12(10): e0185320.

3. Mikkelsen ME, Miliades AN, Gaieski DF, Goyal M, Fuchs BD, Shah CV, Bellamy SL, Christie JD. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009;37(Suppl 5):1670-7.

4. Brian Casserly, Gary S Phillips, Christa Schorr, R Phillip Dellinger, Sean R Townsend, Tiffany M Osborn, Konrad Reinhart, Narendran Selvakumar, Mitchell M Levy. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med. 2015;43(3):567-73.

5. Tae Gun Shin, Ik Joon Jo, Sung Yeon Hwang, Kyeongman Jeon, Gee Young Suh, Euna Choe, Young Kun Lee, Tae Rim Lee, Won Chul Cha, Min Seob Sim. Comprehensive interpretation of central venous oxygen saturation and blood lactate Levels during resuscitation of patients with severe sepsis and septic shock in the emergency department. Shock. 2016;45(1):4-9.

6. Zhang L, Wang H, Li Q, Zhao MH, Zhan QM. Big data and medical research in China. BMJ. 2018; doi: 10.1136/bmj.j5910.

7. Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst. 2014;2:3. doi: 10.1186/2047-2501-2-3.

8. Johnson AE, Pollard TJ, Shen L, Lehman LW, Feng M, Ghassemi M, Moody B, Szolovits P, Celi LA, Mark RG. MIMIC-II, a freely accessible critical care database. Sci Data. 2016; doi: 10.1038/sdata.2016.35.

9. Ghassemi M, Wu M, Hughes MC, Szolovits P, Doshi-velez F. Predicting intervention onset in the ICU with switching state space models. AMIA Summits Transl Sci Proc. 2017; 2017: 82-91.

10. Janice Pan, Shaffer R, Sinno Z, Tyler M, Ghosh J. The obesity paradox in ICU patients. Conf Proc IEEE Eng Med Biol Soc. 2017;2017:3360-4.
11. Sandfort V, Johnson AEW, Kunz LM, Vargas JD, Rosing DR. Prolonged elevated heart rate and 90-day survival in acutely ill patients: data from the MIMIC database. J Intensive Care Med. 2019;34(Suppl 8):622-9.

12. Yao S, Jiang X, Sun C, Zheng Z, Wang B, Wang T. External validation and improvement of life score as a prediction tool in critically ill cirrhosis patients. Hepatol Res. 2018;48(Suppl 11):905-13.

13. Hu ZD, Wei TT, Tang QQ, Fu HT, Yang M, Ma N, Wang LL, Qin BD, Zhou L, Zhong RQ. Prognostic value of red blood cell distribution width in acute pancreatitis patients admitted to intensive care units: an analysis of a publicly accessible clinical database MIMIC II. Clin Chem Lab Med. 2016;54(Suppl 7):e195-7.

14. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2001;2003:530–8.

15. Berg RM, Plovsing RR. Near-infrared spectroscopy versus transcranial Doppler ultrasound for assessing dynamic cerebral autoregulation by transfer function analysis in sepsis. Scand J Clin Lab Invest. 2016;76(Suppl 1):88-91.

16. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M, Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(Suppl 8):775-87.

17. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007;35(Suppl 5):1244-50.

18. Cheng HH, Chen FC, Change MW, Kung CT, Cheng CY, Tsai TC, Hsiao SY, Su CM. Difference between elderly and non-elderly patients in using serum lactate level to predict mortality caused by sepsis in the emergency department. Medicine (Baltimore). 2018;97(Suppl 13):e0209. doi: 10.1097/MD.00000000000010209.

19. Garcia-Alvarez M, Marik P, Bellomo R. Sepsis-associated hyperlactatemia. Crit Care, 2014, 18(5): 503.

20. Singhal R, Coghill JE, Guy A, Bradbury AW, Adam DJ, Scriven JM. Serum lactate and base deficit as predictors of mortality after ruptured abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 2005;30(Suppl 3):263-6.

21. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(Suppl 1):15–21.

22. Blot S, Cankurtaran M, Petrovic M, Vandijck D, Lizy C, Decruyenaere J, Danneels C, Vandewoude K, Piette A, Verschaeren G, et al. Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. Crit Care Med. 2009;37(Suppl 5):1634–41.

23. Liang SY. Sepsis and other infectious disease emergencies in the elderly. Emerg Med Clin North Am. 2016;34(Suppl 3):501–22.

24. Angus DC, Linde-Zwirble WT, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(Suppl 7):1303–10.
25. Haas SA, Lange T, Saugel B, Petzoldt M, Fuhrmann V, Metschke M, Kluge S. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients. Intensive Care Med. 2016;42(2):202-10.

Table

Table 1. Baseline characteristics and clinical outcomes of patients in the two age groups.
| Variable | Non-elderly (n=1249) | Elderly (n=1599)| P value | Non-survivors | Elderly (n=1599)| P value |
|---|---|---|---|---|---|---|
| Age (years) | | | | | | |
| Survivors | Non-survivors | <0.001* | Survivors | Non-survivors | <0.001* |
| 52.99(43.54-59.53) | 55.89(48.89-61.17) | | 78.23(71.77-84.58) | 80.43(72.48-85.82) | 0.009* | <0.001* |
| Sex | | | | | | |
| Male | Female | 0.353 | Male | Female | 0.354 | 0.023* |
| 544(57.08%) | 409(42.92%) | | 542(52.67%) | 487(47.33%) | | |
| ICU length of stay (d) | 4.73(2.43-12.12) | 0.196 | 5.03(2.27-10.16) | 4.38(2.90-8.43) | 0.048 | <0.001* |
| Lactate (mmol/L) | 2.10(1.40-3.40) | <0.001* | 3.20(1.93-5.18) | 2.40(1.68-4.00) | <0.001* | 0.852 |
| Scoring system | | | | | | |
| SAPSII | 36.00(27.00-46.00) | <0.001* | 45.00(37.00-54.00) | 55.00(47.00-66.00) | 0.001* | <0.001* |
| SOFA | 6.00(4.00-9.00) | <0.001* | 6.00(4.00-8.00) | 8.00(6.00-11.00) | <0.001* | 0.013* |
| LODS | 4.00(2.00-6.00) | <0.001* | 6.00(4.00-8.00) | 5.00(3.00-7.00) | <0.001* | 0.557 |
| OASIS | 34.00(27.00-41.00) | <0.001* | 40.00(34.25-47.00) | 43.00(37.00-48.00) | <0.001* | <0.001* |
| QSOFA | <0.001* | | | | | |
| 0 | | | | | | |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| SIRS | | | | | | |
| 0 | | | | | | |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| Ethnicity | | | | | | |
| White | | | | | | |
| Black | | | | | | |
| Asian | | | | | | |
| Hispanic | | | | | | |
| Other or unknown | | | | | | |
| First care unit | | | | | | |
| MICU | | | | | | |
| CCU | | | | | | |
| TSICU | | | | | | |
| CSRU | | | | | | |
| SICU | | | | | | |
| Admission type | | | | | | |
| Emergency | | | | | | |
| Elective | | | | | | |
| Urgent | | | | | | |
| Initial vital signs | | | | | | |
| Heart rate (beats/min) | 96.61(84.67-109.36) | 0.031* | 87.00(75.81-98.77) | 90.85(77.46-105.41) | <0.001* | <0.001* |
| Mean blood pressure (mmHg) | 74.18(69.43-80.44) | <0.001* | 71.03(66.02-76.90) | 69.13(64.48-74.30) | <0.001* | <0.001* |
| Respiratory rate (breaths/min) | 20.98(17.94-24.21) | <0.001* | 20.47(17.79-23.49) | 21.39(18.38-25.06) | <0.001* | 0.013* |
| Body temperature (°C) | 37.18(36.67-37.75) | <0.001* | 36.76(36.22-37.37) | 36.65(36.16-37.14) | <0.001* | <0.001* |
| SpO2 (%) | 97.21(95.88-98.48) | <0.001* | 97.30(95.96-98.50) | 97.04(95.22-98.51) | 0.004 | 0.143 |
Major comorbidities

| Comorbidity                        | Survivors (n=1982) | Non-Survivors (n=866) | P value | Survivors (n=1982) | Non-Survivors (n=866) | P value |
|------------------------------------|--------------------|-----------------------|---------|--------------------|-----------------------|---------|
| Hypertension                       | 388 (40.71%)       | 112 (37.84%)          | 0.378   | 642 (62.39%)       | 340 (59.65%)          | 0.281   |
| Liver cirrhosis                    | 88 (9.23%)         | 108 (36.49%)          | <0.001* | 112 (37.84%)       | 40 (7.02%)            | 0.002*  |
| Congestive heart failure           | 168 (17.63%)       | 60 (20.27%)           | 0.304   | 436 (42.37%)       | 252 (44.21%)          | 0.477   |
| Chronic renal insufficiency        | 520 (54.56%)       | 216 (72.97%)          | <0.001* | 656 (63.75%)       | 421 (73.86%)          | <0.001* |
| Cerebrovascular disease            | 67 (7.03%)         | 22 (7.43%)            | 0.814   | 96 (9.33%)         | 63 (11.05%)           | 0.270   |
| Diabetes mellitus                  | 253 (26.55%)       | 74 (25.00%)           | 0.597   | 355 (34.50%)       | 199 (34.91%)          | 0.868   |
| Malignancy                         | 82 (8.60%)         | 67 (22.64%)           | <0.001* | 103 (10.01%)       | 125 (21.93%)          | <0.001* |

Major source of infection

| Source                             | Survivors (n=1982) | Non-Survivors (n=866) | P value | Survivors (n=1982) | Non-Survivors (n=866) | P value |
|------------------------------------|--------------------|-----------------------|---------|--------------------|-----------------------|---------|
| Respiratory tract                  | 281 (29.49%)       | 83 (28.04%)           | 0.633   | 335 (32.56%)       | 202 (35.44%)          | 0.243   |
| Urinary tract                      | 44 (4.62%)         | 0 (0%)                | <0.001* | 40 (3.89%)         | 9 (1.58%)             | 0.01*   |
| Skin and soft tissue               | 120 (12.59%)       | 19 (6.42%)            | 0.003*  | 86 (8.36%)         | 28 (4.91%)            | 0.01*   |
| Intra-abdomen                      | 149 (15.63%)       | 58 (19.59%)           | 0.11    | 186 (18.08%)       | 75 (13.16%)           | 0.011*  |
| 28-day mortality                   | 296 (32.70%)       | 570 (35.65%)          | <0.001* |                    |                       |         |

*p<0.05

SAPSII, simplified acute physiology score II; SOFA, sequential organ failure assessment; LODS, logistic organ dysfunction system; OASIS, oxford acute severity of illness score; QSOFA, quick sepsis related organ failure assessment; SIRS, systemic inflammatory response syndrome; MICU, medical intensive care unit; CCU, coronary care unit; TSICU, trauma surgical intensive care unit; CSRU, cardiac surgery recovery unit; SICU, surgical intensive care unit; SpO2, peripheral capillary oxygen saturation.

Table 2. Lactate levels in survivors and non-survivors of the two age groups.

| Variable | Survivors(n=1982) | Non-survivors(n=866) | P value |
|----------|-------------------|----------------------|---------|
| Lactate (mmol/L) | Non-elderly (n=953) | Elderly (n=1029) | 0.062   |
|          |                   |                      |         |
|          | 2.10(1.40-3.40)   | 2.20(1.50-3.50)      | <0.001* |

*p<0.05
Table 3. AUC of lactate and some scoring systems for predicting 28-day mortality.

|                | Non-elderly |                         |                         |                | Elderly |                         |                         |                |
|----------------|-------------|-------------------------|-------------------------|----------------|---------|-------------------------|-------------------------|----------------|
|                | AUC (95%CI) | Sensitivity | Specificity | Youden's index | P value | AUC (95%CI) | Sensitivity | Specificity | Youden's index | P value |
| SAPSII         | 0.797(0.76-0.824) | 0.710 | 0.739 | 0.448 | 0.424 | 0.704(0.67-0.730) | 0.775 | 0.539 | 0.315 | 0.587 |
| SAPSII*LA      | 0.800(0.77-0.827) | 0.784 | 0.675 | 0.459 | 0.756 | 0.705(0.67-0.731) | 0.663 | 0.579 | 0.242 | 0.616 |
| SOFA           | 0.761(0.73-0.792) | 0.588 | 0.796 | 0.384 | 0.157 | 0.657(0.62-0.685) | 0.602 | 0.645 | 0.247 |
| SOFA*LAC       | 0.767(0.73-0.798) | 0.628 | 0.787 | 0.415 | 0.658(0.63-0.686) | 0.602 | 0.645 | 0.247 |
| LODS           | 0.723(0.69-0.755) | 0.737 | 0.619 | 0.356 | 0.057 | 0.651(0.62-0.679) | 0.460 | 0.754 | 0.214 | 0.057 |
| LODS*LA        | 0.737(0.70-0.769) | 0.689 | 0.665 | 0.355 | 0.657(0.62-0.685) | 0.507 | 0.729 | 0.236 |
| OASIS          | 0.696(0.66-0.73) | 0.750 | 0.531 | 0.281 | 0.012* | 0.683(0.65-0.709) | 0.744 | 0.513 | 0.257 | 0.431 |
| OASIS*LA       | 0.717(0.68-0.75) | 0.710 | 0.602 | 0.312 | 0.685(0.65-0.712) | 0.723 | 0.548 | 0.271 |
| QSOFA          | 0.569(0.53-0.6) | 0.932 | 0.162 | 0.094 | <0.001* | 0.561(0.53-0.59) | 0.309 | 0.783 | 0.092 | 0.003* |
| QSOFA*LA       | 0.668(0.63-0.704) | 0.757 | 0.503 | 0.259 | 0.591(0.56-0.62) | 0.442 | 0.710 | 0.153 |
| SIRS           | 0.516(0.47-0.55) | 0.544 | 0.488 | 0.032 | <0.001* | 0.546(0.51-0.57) | 0.890 | 0.180 | 0.069 | 0.038* |
| SIRS*LAC       | 0.661(0.62-0.697) | 0.723 | 0.523 | 0.246 | 0.569(0.54-0.598) | 0.861 | 0.236 | 0.098 |
| Lactate        | 0.661(0.62-0.697) | 0.723 | 0.523 | 0.246 | 0.553(0.52-0.582) | 0.204 | 0.880 | 0.083 |

*P<0.05

Table 4. Relationship between lactate and 28-day mortality in different models.
|                | Non-adjusted OR (95%CI) | P value | Adjusted I OR (95%CI) | P value | Adjusted II OR (95%CI) | P value |
|----------------|-------------------------|---------|-----------------------|---------|------------------------|---------|
| **Non-elderly**|                         |         |                       |         |                        |         |
| Lactate (mmol/L) | 1.28 (1.21-1.35)        | <0.001* | 1.29 (1.22-1.37)      | <0.001* | 1.16 (1.09-1.23)       | <0.001* |
| Lactate level   |                         |         |                       |         |                        |         |
| 0.30-1.60       | 1.00                    |         | 1.00                  |         | 1.00                   |         |
| 1.70-3.10       | 1.75 (1.21-2.53)        | 0.003*  | 1.76 (1.21-2.55)      | 0.003*  | 1.50 (1.00-2.25)       | 0.048*  |
| 3.20-24.70      | 3.40 (2.41-4.82)        | <0.001* | 3.53 (2.48-5.02)      | <0.001* | 2.07 (1.40-3.06)       | <0.001* |
| p for trend     | 1.86 (1.57-2.20)        | <0.001* | 1.89 (1.59-2.25)      | <0.001* | 1.43 (1.18-1.73)       | <0.001* |
| **Elderly**     |                         |         |                       |         |                        |         |
| Lactate (mmol/L) | 1.11 (1.06-1.17)        | <0.001* | 1.12 (1.06-1.17)      | <0.001* | 1.03 (0.98-1.08)       | 0.290   |
| Lactate level   |                         |         |                       |         |                        |         |
| 0.30-1.70       | 1.00                    |         | 1.00                  |         | 1.00                   |         |
| 1.80-3.00       | 1.22 (0.94-1.57)        | 0.130   | 1.24 (0.96-1.61)      | 0.099   | 1.15 (0.87-1.51)       | 0.324   |
| 3.10-17.40      | 1.47 (1.14-1.89)        | 0.003*  | 1.50 (1.16-1.94)      | 0.002*  | 1.03 (0.78-1.36)       | 0.815   |
| p for trend     | 1.21 (1.07-1.37)        | 0.003*  | 1.23 (1.08-1.39)      | 0.002*  | 1.02 (0.89-1.16)       | 0.830   |

*P<0.05

Non-adjusted model adjust for: None
Adjust I model adjust for: age; gender; ethnicity.
Adjust II model adjust for: age; gender; first care unit; SAPSII.

Table 5. Subgroup analysis of the association between lactate and 28-day mortality in the two age groups.
| Subgroup | Non-elderly | Elderly | p for interaction |
|----------|-------------|---------|------------------|
| **Sex**  |             |         | 0.775            | 0.102            |
| Male     | 722         | 1.27 (1.19-1.36) |              | 1.15 (1.08-1.22) |
| Female   | 527         | 1.29 (1.17-1.42) |              | 1.06 (0.98-1.14) |
| **Ethnicity** |             | 0.317 |         | 0.278            |
| White    | 851         | 1.32 (1.22-1.42) |              | 1.09 (1.03-1.15) |
| Black    | 137         | 1.25 (1.07-1.46) |              | 1.24 (1.02-1.51) |
| Asian    | 40          | 1.34 (1.01-1.76) |              | 1.13 (0.88-1.46) |
| Hispanic | 58          | 1.72 (1.14-2.60) |              | 1.42 (0.98-2.06) |
| Other or unknown | 163         | 1.18 (1.05-1.33) |              | 1.20 (1.04-1.40) |
| **First care unit** | 0.141 |         | 0.485 |         |
| MICU     | 852         | 1.30 (1.22-1.40) |              | 1.09 (1.03-1.15) |
| CCU      | 84          | 1.29 (1.04-1.60) |              | 1.16 (1.00-1.34) |
| TSICU    | 87          | 1.03 (0.85-1.25) |              | 1.18 (0.98-1.42) |
| CSRU     | 31          | 0.83 (0.33-2.06) |              | 1.07 (0.86-1.34) |
| SICU     | 195         | 1.34 (1.16-1.56) |              | 1.24 (1.06-1.46) |
| **Admission type** | 0.762 |         | 0.858 |         |
| Emergency| 1175        | 1.27 (1.20-1.35) |              | 1.11 (1.06-1.17) |
| Elective | 50          | 1.39 (0.93-2.08) |              | 1.17 (0.91, 1.52) |
| Urgent   | 24          | 1.44 (0.94, 2.19)|              | 1.21 (0.78, 1.86) |
| SAPSII   | 11.00-28.00 | 1.52 (1.03-2.25) | 12.00-39.00   | 0.94 (0.77-1.14) |
|          | 29.00-38.00 | 0.99 (0.82-1.20) | 40.00-48.00   | 0.99 (0.88-1.11) |
|          | 39.00-51.00 | 1.09 (0.99-1.20) | 49.00-58.00   | 1.11 (1.01-1.22) |
|          | 52.00-107.00| 1.27 (1.15-1.40)| 59.00-110.00  | 1.05 (0.97-1.13) |
| SOFA     | 0.00-3.00   | 1.85 (1.28-2.68) | 0.00-3.00     | 1.09 (0.93-1.29) |
|          | 4.00-6.00   | 0.99 (0.82-1.19) | 4.00-6.00     | 0.94 (0.83-1.06) |
|          | 7.00-9.00   | 1.18 (1.05-1.32) | 7.00-8.00     | 1.04 (0.93-1.15) |
|          | 10.00-21.00 | 1.17 (1.09-1.27) | 9.00-21.00    | 1.13 (1.05-1.21) |
| QSOFA    | 0           | 0.88 (0.32, 2.39)| 0             | 1.00 (0.00, inf.) |
|          | 1           | 1.16 (0.93, 1.44)| 1             | 1.00 (0.85, 1.18) |
|          | 2           | 1.27 (1.19, 1.35)| 2             | 1.14 (1.07, 1.21) |
|          | 3           | 1.33 (1.16, 1.52)| 3             | 1.09 (0.99, 1.19) |
| SIRS     | 0.432       | 1.00 (0.00-Inf)| 0             | 1.00 (0.00, inf.) |
|          | 1           | 0.70 (0.28-1.75)| 1             | 1.65 (0.99-2.77) |
|          | 2           | 1.20 (0.98-1.46)| 2             | 1.30 (1.09-1.55) |
|          | 3           | 1.35 (1.21-1.50)| 3             | 1.05 (0.96-1.14) |
|          | 4           | 1.27 (1.18-1.36)| 4             | 1.10 (1.04-1.17) |
| **Major comorbidities** |         | 0.699 |         | 0.257            |
| Hypertension |             |         |         | 0.874            |
| No       | 749         | 1.29 (1.20-1.39)|              | 1.08 (1.01-1.16) |
| Yes      | 500         | 1.26 (1.16-1.37)|              | 1.14 (1.07-1.22) |
| Liver cirrhosis |         | 0.027 |         | 0.087            |
| No       | 1053        | 1.28 (1.19-1.36)|              | 1.11 (1.06-1.16) |
| Yes      | 196         | 1.10 (0.99-1.22)|              | 1.12 (0.95-1.33) |
| Congestive heart failure |         | 0.246 |         | 0.266            |
| No       | 1021        | 1.30 (1.22-1.38)|              | 1.15 (1.09-1.23) |
| Yes      | 228         | 1.19 (1.04-1.36)|              | 1.06 (0.99-1.14) |
|                          | No     | Yes  | 95% CI          | No     | Yes  | 95% CI          |
|--------------------------|--------|------|-----------------|--------|------|-----------------|
| Cerebrovascular disease  |        |      |                 |        |      |                 |
| No                       | 513    | 736  | 1.32 (1.18-1.47)| No     | 522  | 1.05 (0.95-1.16)|
| Yes                      |        |      | 1.24 (1.16-1.32)| Yes    | 1077 | 1.12 (1.06-1.18)|
|                          | 0.786  |      |                 | 0.645  |      |                 |
| Diabetes mellitus        |        |      |                 |        |      |                 |
| No                       | 1160   | 89   | 1.28 (1.21, 1.36)| No     | 1440 | 1.12 (1.06, 1.17)|
| Yes                      | 922    |      | 1.24 (1.00, 1.54)| Yes    | 159  | 1.08 (0.93, 1.25)|
|                          | 0.584  |      |                 | 0.825  |      |                 |
| Malignancy               |        |      |                 |        |      |                 |
| No                       | 1100   | 327  | 1.29 (1.21-1.38)| No     | 1045 | 1.12 (1.06-1.18)|
| Yes                      | 922    |      | 1.25 (1.12-1.38)| Yes    | 554  | 1.11 (1.02-1.20)|
|                          | 0.584  |      |                 | 0.600  |      |                 |
| Major source of infection|        |      |                 |        |      |                 |
| Respiratory tract        |        |      |                 |        |      |                 |
| No                       | 885    | 364  | 1.32 (1.23-1.41)| No     | 1062 | 1.16 (1.09-1.22)|
| Yes                      | 1205   |      | 1.18 (1.05-1.31)| Yes    | 537  | 1.04 (0.95-1.13)|
|                          | 0.088  |      |                 | 0.036* |      |                 |
| Urinary tract            |        |      |                 |        |      |                 |
| No                       | 1205   | 44   | 1.27 (1.20, 1.34)| No     | 1550 | 1.12 (1.06, 1.17)|
| Yes                      | 885    |      | 1.00 (0.00, inf.)| Yes    | 49   | 1.07 (0.70, 1.64)|
|                          | 1.000  |      |                 | 0.844  |      |                 |
| Skin and soft tissue     |        |      |                 |        |      |                 |
| No                       | 1110   | 139  | 1.29 (1.22-1.37)| No     | 1485 | 1.11 (1.06-1.17)|
| Yes                      | 1042   |      | 1.06 (0.84-1.35)| Yes    | 114  | 1.12 (0.94-1.33)|
|                          | 0.010  |      |                 | 0.966  |      |                 |
| Intra-abdomen            |        |      |                 |        |      |                 |
| No                       | 207    | 261  | 1.54 (1.33-1.79)| No     | 1338 | 1.12 (1.06-1.18)|
| Yes                      | 207    |      | 1.41 (1.01-1.93)| Yes    | 261  | 1.08 (0.95-1.23)|
|                          | 0.003* |      |                 | 0.656  |      |                 |

*P<0.05

Figures
Figure 1. Patient disposition.

Figure 1

Patient disposition.
Figure 2. Receiver operating characteristic curves for predicting 28-day mortality in non-elderly patients.

**Figure 2**

Receiver operating characteristic curves for predicting 28-day mortality in non-elderly patients.
Figure 3. Receiver operating characteristic curves for predicting 28-day mortality in elderly patients.
Figure 4. Subgroup analysis of the association between lactate and 28-day mortality in non-elderly patients.

Subgroup analysis of the association between lactate and 28-day mortality in non-elderly patients.